Funding for this research was provided by:
the Science and Technology Planning Project of Guangdong Province, China (No. 2017A030223006, 2016A020215128)
the Science and Technology Planning Project of Guangzhou, China (No. 201704020077)
the Second Batch of Scientific Research Projects of Dengfeng Plan (NO. DFJH201913)
the Research Fund of CSCO-Roche Oncology (NO. Y-2019Roche-190)
the Research Fund of CSCO-Hansoh Oncology (NO. Y-HS2019/2-050)
the Research Fund of Guangdong General Hospital (No. y012015338)
the Yuexiu Science and Information Center of Guangzhou Scientific Foundation (No. 2012‑GX‑046)
Received: 5 August 2020
Accepted: 27 January 2021
First Online: 17 February 2021
Ethics approval and consent to participate
: This study was approved by the Ethics Committee of Guangdong Provincial People’s Hospital [No. GDREC2019296H(R1)] and was carried out in adherence with the Declaration of Helsinki.The need for informed consent from all patients was waived due to the study’s retrospective nature.The data that support the findings of this study are available from the corresponding author upon reasonable request.
: Not applicable.
: The authors declare that they have no competing interests.